- Home
- GAMB vs AARD Comparison
GAMB vs AARD Comparison
Compare GAMB & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GAMB | AARD |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | Jersey | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.9M | 231.9M |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | GAMB | AARD |
|---|---|---|
| Price | $5.62 | $14.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $11.83 | ★ $30.63 |
| AVG Volume (30 Days) | ★ 847.5K | 219.1K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $154,519,000.00 | N/A |
| Revenue This Year | $32.43 | N/A |
| Revenue Next Year | $12.90 | N/A |
| P/E Ratio | $118.41 | ★ N/A |
| Revenue Growth | ★ 24.21 | N/A |
| 52 Week Low | $4.60 | $4.88 |
| 52 Week High | $17.14 | $19.58 |
Technical Indicators
Market Signals| Indicator | GAMB | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 45.73 | 64.16 |
| Support Level | $5.30 | $12.54 |
| Resistance Level | $5.54 | $16.00 |
| Average True Range (ATR) | 0.23 | 1.01 |
| MACD | 0.14 | 0.58 |
| Stochastic Oscillator | 78.95 | 76.10 |
Price Performance
Historical ComparisonAbout GAMB Gambling.com Group Limited
Gambling.com Group Ltd is a multi-award-winning performance marketing company and a provider of digital marketing services in the online gambling industry. Its principal focus is on online casinos online sports betting and the fantasy sports industry. It generates revenue by referring online gamblers to online gambling operators.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.